

PROJECT CLEANSE

BUSINESS OVERVIEW



A unique opportunity exists to acquire the shares of Project Cleanse, a biotechnology company addressing biofilm prevention through a patented, non-biocidal mechanism.

Originating from major corporate R&D, the technology relates to a platform of synthetic lactam quorum-sensing inhibitors designed to prevent damaging biofilms, which can cause bacterial shedding, infections and accelerate erosion of materials including concrete and steel.

The Company operates an asset-light model, with the core patented technology underpinning its operations licensed from a leading multinational corporation. The Company holds exclusive worldwide rights across the textiles, healthcare, coatings, and industrial cleaning fields, and the head license grants the Company permission to sublicense and commercially exploit the patent portfolio.

The technology, which is the product of 14 years worth of development and c.£13m of investment, has been validated in regulated healthcare markets and is positioned for multi-sector deployment, with commercial traction to date achieved via sublicensing into the healthcare market.

In order to facilitate the transfer of the existing head licensing agreement, along with all associated regulatory and contractual assets, the Company is soliciting offers for 100% of its issued share capital.

OPPORTUNITY HIGHLIGHTS



- Technology & IP Portfolio:** 23 patent families with global coverage, developed in conjunction with leading MNC, which operates as an existing shareholder.
- Significant Addressable Market:** This includes Textiles (\$28.5bn), Healthcare (\$2.5bn), Paints & Coatings (\$17bn) and Industrial Cleaning (\$75bn).
- Key Regulatory Milestones:** Critical regulatory approval achieved including UK & EU REACH, along with FDA & Health Canada clearance for dental medical device.
- Existing Commercial Traction:** Initial revenues from healthcare, with active partnerships across textiles, coatings, and cleaning.

ASSETS FEATURED



- Exclusive IP Licence:** Worldwide rights across textiles, healthcare, coatings, and industrial cleaning.
- Regulatory Assets:** UK & EU REACH registration (2025); FDA & Health Canada clearance for dental medical device.
- Proprietary Know-how & Data:** Relating to manufacturing processes, formulation methods, analytical protocols and efficacy datasets
- Brand-related Assets:** Includes registered trade marks and domain portfolio

DEADLINE



A deadline for initial expressions of interest has been set for **Friday 23 January 2025 at 12pm (GMT)**, with a deadline for final offers to be set shortly after.

FURTHER INFORMATION

Requests for further information should be addressed to Emily Muir or Emre Turan of Gordon Brothers. Contact details have been provided.

Access to additional information can be provided upon receipt of a signed NDA. All offers are to be supported by proof of funding.



EMILY MUIR

emuir@gordonbrothers.com
+44 (0) 7442 936 429



EMRE TURAN

eturan@gordonbrothers.com
+44 (0) 7471 996 068